European Commission continues to probe for anti-competitive patent settlements
This article was originally published in SRA
Executive Summary
The number of pharmaceutical firms contriving illegal agreements to extend the monopoly of branded drugs appears to be coming down, but the European Commission has, for a second time, asked companies for information on patent settlements concluded between originators and generic medicines companies1. Companies are getting better at responding to the commission's inquiries, says Stephen Whitfield, an associate at the law firm, Taylor Wessing2.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.